Regencell Bioscience Holdings (Regencell Bioscience Holdings) EBIT

: $-6.27 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Regencell Bioscience Holdings's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was $-2.84 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-6.27 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Regencell Bioscience Holdings's annualized ROC % for the quarter that ended in Jun. 2023 was -66.97%. Regencell Bioscience Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -75.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Regencell Bioscience Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -16.88%.

Regencell Bioscience Holdings EBIT Historical Data

The historical data trend for Regencell Bioscience Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

-0.39

-0.81

-1.38

-7.62

-6.27

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT					-1.01	-3.66	-3.96	-3.43	-2.84

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's EV-to-EBIT falls into.

Regencell Bioscience Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.27 Mil.

Regencell Bioscience Holdings (NAS:RGC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Regencell Bioscience Holdings's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-5.688 * ( 1 - 0% )	/	( (15.548	+	1.439)	/ 2 )
=	-5.688	/	8.4935
=	-66.97 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15.548	-	0	-	( 0	-	max(0, 0	-	14.192	+	0	))
=	15.548

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.622	-	0.169	-	( 11.565	-	max(0, 0.607	-	11.621	+	11.565	))
=	1.439

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Regencell Bioscience Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.688	/	( ( (0 + max(14.192, 0))	+	(0.892 + max(-0.17, 0)) )	/	2 )
=	-5.688	/	( ( 14.192	+	0.892 )	/	2 )
=	-5.688	/	7.542
=	-75.42 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	14.192)	-	(0	+	0	+	0)
=	14.192

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	-0.00099999999999945)	-	(0.169	+	0	+	0)
=	-0.17

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Regencell Bioscience Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-6.274	/	37.177
	=	-16.88 %

Regencell Bioscience Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.